teferrol and Inflammatory-Bowel-Diseases

Iron deficiency is a common complication of inflammatory bowel disease. Oral iron therapy may reinforce intestinal tissue injury by catalyzing production of reactive oxygen species.. To compare the effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage and clinical disease activity in patients with inflammatory bowel disease.. Forty-one patients with inflammatory bowel disease and iron deficiency were randomized to treatment with ferrous sulphate 100 mg twice a day or iron-polymaltose complex 200 mg once a day for 14 days.. Following ferrous sulphate, plasma malondialdehyde increased (P = 0.02), while urine 8-isoprostaglandin F(2alpha) and plasma antioxidants did not change significantly. Iron-polymaltose complex did not change plasma malondialdehyde, urine 8-isoprostaglandin F(2alpha) or plasma antioxidants. Comparing the two treatments, changes in plasma malondialdehyde tended to differ (P = 0.08), while urine 8-isoprostaglandin F(2alpha) and plasma antioxidants did not differ. Neither ferrous sulphate nor iron-polymaltose complex altered clinical disease activity indices.. Ferrous sulphate increased plasma malondialdehyde, a marker of lipid peroxidation. Comparing treatment with ferrous sulphate and iron-polymaltose complex, changes in plasma malondialdehyde tended to differ. Clinical disease activity was unchanged after both treatments.

Topics: Adolescent; Adult; Aged; Antioxidants; Biomarkers; Dinoprost; Female; Ferric Compounds; Ferrous Compounds; Hematinics; Humans; Inflammatory Bowel Diseases; Iron Deficiencies; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Oxidative Stress; Prospective Studies; Reactive Oxygen Species; Tablets; Vasoconstrictor Agents

Topics: Administration, Oral; Anemia, Iron-Deficiency; Cholecalciferol; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Injections, Intramuscular; Maltose; Vitamin D Deficiency

Intravenous correction of iron deficiency by total dose iron polymaltose is inexpensive and safe, but current protocols entail prolonged administration over more than 4 h. This results in reduced patient acceptance, and hospital resource strain. We aimed to assess prospectively the safety of a rapid intravenous protocol and compare this with historical controls.. Consecutive patients in whom intravenous iron replacement was indicated were invited to have up to 1.5 g iron polymaltose by a 58-min infusion protocol after an initial 15-min test dose without pre-medication. Infusion-related adverse events (AE) and delayed AE over the ensuing 5 days were also prospectively documented and graded as mild, moderate or severe.. One hundred patients, 63 female, mean age 54 (range 18-85) years were studied. Thirty-four infusion-related AE to iron polymaltose occurred in a total of 24 patients--25 mild, 8 moderate and 1 severe; higher than previously reported for a slow protocol iron infusion. Thirty-one delayed AE occurred in 26 patients--26 mild, 3 moderate and 2 severe; similar to previously reported. All but five patients reported they would prefer iron replacement through the rapid protocol again. The presence of inflammatory bowel disease (IBD) predicted infusion-related reactions (54% vs 14% without IBD, P < 0.001) and the serum C-reactive protein was higher in those with reactions (P = 0.043).. Iron polymaltose can be successfully administered using a rapid total dose infusion protocol and was well accepted by patients. It offers significant cost, resource utilization and time benefits for the patient and hospital system.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Clinical Protocols; Female; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Middle Aged; Polysaccharides; Prospective Studies; Time Factors; Young Adult

The rate of infusion reactions to total-dose intravenous iron polymaltose is very low, but the frequency and severity of adverse reactions following the infusion are unknown. In 50 consecutive patients, adverse reactions developed up to 2 days after the infusion in 26% and lasted 1-8 days (median 4). Severe systemic reactions occurred in 8%. Patients should be warned of the chance of delayed reactions and an alternative iron preparation should be considered if parenteral iron is again indicated.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthralgia; Celiac Disease; Female; Ferric Compounds; Fever; Gastrointestinal Diseases; Headache; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron Deficiencies; Malabsorption Syndromes; Male; Middle Aged; Stomach Diseases; Young Adult